$PDSB For a second try to digest how important this data is for R/R advanced HPV malignancies. 1) 1st line Chemo and or Radiation Tx, if fails followed by CI therapy. 2) ORR is about 12-24% with Checkpoint Inhibitors for R/R cancer that doesn’t respond to chemo/radiation tx. 3) BintraFusp alfa highest ORR so far close to 30% who are CI naive. 4) BintraFusp alfa showed ORR close to 10% in advanced HPV refractory to CI therapy. 5) Now PDS0101 triplet therapy shows an ORR of 10/14 (71%). Not sure why some biotech analysts ignoring this data